Biogen Inc. (BIIB)
After hours:
| Previous close | 291.92 |
| Open | 292.36 |
| Bid | 279.00 x 800 |
| Ask | 290.66 x 2200 |
| Day's range | 289.94 - 295.89 |
| 52-week range | 187.16 - 311.88 |
| Volume | |
| Avg. volume | 1,233,708 |
| Market cap | 42.611B |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | 15.04 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
CAMBRIDGE, Mass., December 06, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a rapid-acting, once-daily, 14-day oral short course treatment in adults with MDD and PPD. The submission
- Business Wire
GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY®
SANTA MONICA, Calif., October 13, 2022--GoodRx (NASDAQ: GDRX), a leading consumer-focused digital healthcare platform, today announced a collaboration with Biogen (NASDAQ: BIIB) that aims to improve the patient and healthcare provider (HCP) experience when initiating a new specialty therapy. HCPs who have decided to start patients with relapsing forms of multiple sclerosis (MS) on VUMERITY® (diroximel fumarate) may now find the enrollment form and submit to the specialty hub through Provider Mod
- Business Wire
Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform
CAMBRIDGE, Mass. & NEW YORK, June 22, 2022--Biogen (NASDAQ:BIIB) and Happify Health (www.HappifyHealth.com), the Intelligent Healing Company™, today announced a collaboration to provide a digital solution for patient education and engagement, powered by artificial intelligence (AI), to support people living with multiple sclerosis (MS). Through this collaboration, Biogen and Happify Health will help people with MS manage their care journey, improve their wellbeing, learn about treatment options,
